Chief Commercial Officer (CCO)

Veracyte initiated with neutral view at Canaccord, here's why

Freedom Capital Markets Initiates Coverage of Veracyte With Buy Rating and $45 Price Target

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte Insider Sold Shares Worth $753,204, According to a Recent SEC Filing

Associate IP Counsel

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions. They are seeking an Associate IP Counsel to help shape the future of their intellectual property strategy, collaborating with various teams to identify and protect IP assets.

Sign up with Google

Sign in with Google